Gilead boasts its best growth since 2015 de­spite plung­ing sales of Covid treat­ment

Gilead sur­passed Wall Street and an­a­lyst ex­pec­ta­tions for Q4 earn­ings. Com­pa­ny lead­ers said Thurs­day that Gilead is in a cy­cle of in­vest­ment, tout­ing its launch of HIV drug Sun­len­ca and can­cer treat­ments.

The com­pa­ny had $7.4 bil­lion in to­tal Q4 2022 rev­enue and prod­uct sales in­creased 2% to $7.3 bil­lion com­pared to the same pe­ri­od in 2021, dri­ven large­ly by drugs in on­col­o­gy and HIV.

HIV drug Bik­tarvy led the pack, bring­ing in $10.4 bil­lion over the course of 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER